Phase I clinical trial of SYL040012, a small interfering RNA targeting β-adrenergic receptor 2, for lowering intraocular pressure

Molecular Therapy

Volumn 22, Issue 1, 2014, Pages 226-232

  Moreno Montañés, Javier ^a   Sádaba, Belén ^a   Ruz, Verónica ^b   Gómez Guiu, Almudena ^a   Zarranz, Javier ^a   González, María Victoria ^b   Pañeda, Covadonga ^b   Jimenez, Ana Isabel ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Sylentis   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS ACTING ON THE EYE; SYL 040012; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLAUCOMA; HEADACHE; HUMAN; HUMAN EXPERIMENT; INTRAOCULAR PRESSURE; LOW DRUG DOSE; MALE; MUSCLE SPASM; NORMAL HUMAN; OCULAR PRURITUS; OUTCOME ASSESSMENT; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; REPEATED DRUG DOSE; VITAL SIGN;

ADOLESCENT; ADULT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTRAOCULAR PRESSURE; MALE; OPHTHALMIC SOLUTIONS; RECEPTORS, ADRENERGIC, BETA-2; RNA INTERFERENCE; RNA, SMALL INTERFERING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891834550     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.217     Document Type: Article

References (26)

1. Fire, A, Xu, S, Montgomery, MK, Kostas, SA, Driver, SE and Mello, CC (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811
2. Elbashir, SM, Harborth, J, Lendeckel, W, Yalcin, A, Weber, K and Tuschl, T (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498
3. Zamore, PD, Tuschl, T, Sharp, PA and Bartel, DP (2000). RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101: 25-33
4. Lu, PY, Xie, F and Woodle, MC (2005). In vivo application of RNA interference: From functional genomics to therapeutics. Adv Genet 54: 117-142
5. Behlke, MA (2006). Progress towards in vivo use of siRNAs. Mol Ther 13: 644-670
6. Wooddell, CI, Rozema, DB, Hossbach, M, John, M, Hamilton, HL, Chu, Q et al. (2013). Hepatocyte-targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Mol Ther 21: 973-985
7. Ahmed, Z, Kalinski, H, Berry, M, Almasieh, M, Ashush, H, Slager, N et al. (2011). Ocular neuroprotection by siRNA targeting caspase-2. Cell Death Dis 2: E173
8. Nguyen, QD, Schachar, RA, Nduaka, CI, Sperling, M, Basile, AS, Klamerus, KJ et al.; PF-04523655 Study Group. (2012). Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients. Eye (Lond) 26: 1099-1105
9. DeVincenzo, J, Lambkin-Williams, R, Wilkinson, T, Cehelsky, J, Nochur, S, Walsh, E et al. (2010). A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci USA 107: 8800-8805
10. Prokofyeva, E and Zrenner, E (2012). Epidemiology of major eye diseases leading to blindness in Europe: A literature review. Ophthalmic Res 47: 171-188
11. Coleman, AL and Miglior, S (2008). Risk factors for glaucoma onset and progression. Surv Ophthalmol 53 (suppl. 1): S3-10
12. De Natale, R, Le Pen, C and Berdeaux, G (2011). Efficiency of glaucoma drug regulation in 5 European countries: A 1995-2006 longitudinal prescription analysis. J Glaucoma 20: 234-239
13. Singh, K and Shrivastava, A (2011). Medical management of glaucoma: Principles and practice. Indian J Ophthalmol 59 (suppl.): S88-S92
14. Gupta, SK, Agarwal, R, Galpalli, ND, Srivastava, S, Agrawal, SS and Saxena, R (2007). Comparative efficacy of pilocarpine, timolol and latanoprost in experimental models of glaucoma. Methods Find Exp Clin Pharmacol 29: 665-671
15. Servat, JJ and Bernardino, CR (2011). Effects of common topical antiglaucoma medications on the ocular surface, eyelids and periorbital tissue. Drugs Aging 28: 267-282
16. Han, JA, Frishman, WH, Wu Sun, S, Palmiero, PM and Petrillo, R (2008). Cardiovascular and respiratory considerations with pharmacotherapy of glaucoma and ocular hypertension. Cardiol Rev 16: 95-108
17. Jimenez, A, González, V, Panizo, G and Martínez, T (2010). SYL040012 a new treatment for glaucoma: Pharmacokinetics and mechanism of action. ARVO Meeting Abstracts 51: 176
18. Bucolo, C, Salomone, S, Drago, F, Reibaldi, M, Longo, A and Uva, MG (2013). Pharmacological management of ocular hypertension: Current approaches and future prospective. Curr Opin Pharmacol 13: 50-55
19. Haupenthal, J, Baehr, C, Kiermayer, S, Zeuzem, S and Piiper, A (2006). Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum. Biochem Pharmacol 71: 702-710
20. Kain, H, Goldblum, D, Geudelin, B, Thorin, E and Beglinger, C (2009). Tolerability and safety of GS-101 eye drops, an antisense oligonucleotide to insulin receptor substrate-1: A 'first in man' phase I investigation. Br J Clin Pharmacol 68: 169-173
21. Nieminen, T, Lehtimäki, T, Mäenpää, J, Ropo, A, Uusitalo, H and Kähönen, M (2007). Ophthalmic timolol: Plasma concentration and systemic cardiopulmonary effects. Scand J Clin Lab Invest 67: 237-245
22. Renard, P, Kovalski, JL, Cochereau, I, Jaulerry, S, Williamson, W, Elena, PP et al. (2005). Comparison of carteolol plasmatic levels after repeated instillations of long-acting and regular formulations of carteolol 2% in glaucoma patients. Graefes Arch Clin Exp Ophthalmol 243: 1221-1227
23. Yoshida, K, Tanihara, H, Hiroi, K and Honda, Y (1998). Prognostic factors for hypotensive effects of isopropyl unoprostone in eyes with primary open-angle glaucoma. Jpn J Ophthalmol 42: 417-423
24. Bian, Y, Zhou, W, Zhao, Y, Li, X, Geng, W, Hao, R et al. (2011). High-dose siRNAs upregulate mouse Eri-1 at both transcription and posttranscription levels. PLoS ONE 6: E26466
25. Jimenez, A, Mediero, A, Loma, P, Pintor, J, Peral, A and Gonzalez, V (2009). Efficacy of topically administered siRNAs in glaucoma treatment: In vivo results in hypertensive model. ARVO Meeting Abstracts 50: 4054
26. (2006). Common Terminology Criteria for Adverse Events v3.0